AAV Vector Delivery of Progranulin to CNS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as frontotemporal dementia, Alzheimer's, and amyotrophic lateral sclerosis lack therapeutic avenues that effectively target underlying neurodegeneration, with existing therapies mainly focusing on symptom alleviation rather than addressing the underlying causes.
Innovation Solution
The use of adeno-associated viral (AAV) vectors to deliver codon-optimized transgenes encoding therapeutic proteins like progranulin (PGRN) directly to the central nervous system, minimizing expression in peripheral tissues, thereby promoting therapeutic protein expression in the brain to address neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic administration of therapeutic proteins is used to treat neurodegenerative diseases, then the therapeutic protein can reach peripheral tissues, but the protein fails to achieve sufficient concentration in the central nervous system and may cause peripheral side effects
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediaries to deliver therapeutic proteins directly to the central nervous system. The AAV vector acts as a mediator that transports the therapeutic protein gene across the blood-brain barrier, enabling localized expression in the CNS without requiring systemic administration, thereby avoiding peripheral side effects while achieving sufficient therapeutic concentration in the target organ.
Solution Approach 2:
The patent employs tissue-specific promoters (such as synapsin promoter for neurons, GFAP promoter for astrocytes, orIBA-1 promoter for microglia) to drive expression of the therapeutic protein only in specific cell types within the CNS. This local quality approach ensures that the therapeutic protein is produced precisely where needed in the central nervous system, maximizing therapeutic efficacy while minimizing off-target effects in peripheral tissues.
2Duration of action of stationary object
If gene therapy approaches are used to deliver therapeutic transgenes, then sustained protein expression can be achieved, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent incorporates all necessary regulatory elements (promoters, enhancers, polyadenylation signals) and therapeutic gene sequences into the AAV vector construct before administration. This preliminary preparation ensures that once the vector is delivered to the CNS, the therapeutic protein expression can proceed autonomously without requiring further external intervention, thereby achieving sustained expression while keeping the treatment protocol relatively simple.
Solution Approach 2:
The AAV vector system is designed to be self-sufficient within the target cells. The vector contains all necessary genetic elements for transcription and translation, and the therapeutic protein is expressed autonomously once the vector establishes itself in the target cells. This self-service mechanism eliminates the need for repeated administrations or complex external support systems, maintaining simplicity while achieving long-term expression.
Data Source
AI summary
Described herein are methods for treating a subject having or at risk of developing a disorder affecting the central nervous system (CNS) (e.g., a neurocognitive disorder, a neuromuscular disorder, or a neurodegenerative disorder (such as FTD, AD, PD, dementia with Lewy bodies, ALS, or a related neurocognitive or motor neuron disorder) or a lysosomal storage disorder). The methods of the disclosure may include administering an adeno-associated viral (AAV) vector that expresses a therapeutic protein (e.g., whose deficiency or lack of activity is associated with the disorder or whose supplementation is likely to benefit the patient). The AAV vectors of the disclosure may be administered, e.g., in particular quantities and by way of particular routes of administration that achieve gene expression in the CNS while avoiding transduction in peripheral tissues (e.g., liver, lung, and spleen).